- Home
- Publications
- Publication Search
- Publication Details
Title
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-12
DOI
10.1007/s11523-021-00796-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A regional population‐based hereditary breast cancer screening tool in Italy: First 5‐year results
- (2020) Laura Cortesi et al. Cancer Medicine
- PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
- (2020) Ahrum Min et al. Cancers
- Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
- (2020) Nadine M. Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy
- (2020) Angela Toss et al. Cancers
- Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
- (2020) P.A. Fasching et al. ANNALS OF ONCOLOGY
- Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Véronique Diéras et al. LANCET ONCOLOGY
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
- (2020) Nadine M. Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer
- (2019) Carol Forbes et al. Cancer Management and Research
- The global and regional survival rate of women with breast cancer: A systematic review and meta-analysis
- (2019) Khadije Maajani et al. Clinical Breast Cancer
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
- (2019) David Michael Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
- (2019) Joshua James Gruber et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes associated with rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis.
- (2019) Kelly A. Metcalfe et al. JOURNAL OF CLINICAL ONCOLOGY
- Early results from the BRCA Founder Outreach (BFOR) Study: Population genetic screening using a medical model.
- (2019) Kelly Morgan et al. JOURNAL OF CLINICAL ONCOLOGY
- Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
- (2019) Sarah Sammons et al. JOURNAL OF CLINICAL ONCOLOGY
- VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).
- (2019) Andrew Tutt et al. JOURNAL OF CLINICAL ONCOLOGY
- RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).
- (2019) Anne Patsouris et al. JOURNAL OF CLINICAL ONCOLOGY
- Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer.
- (2019) Charles McCrea et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
- (2019) Zahi Ibrahim Mitri et al. JOURNAL OF CLINICAL ONCOLOGY
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- A systematic review of the international prevalence of BRCA mutation in breast cancer
- (2019) Nigel Armstrong et al. Clinical Epidemiology
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
- (2019) Carl M. Gay et al. Journal of Thoracic Oncology
- 384TiPEffectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study
- (2019) J E Alés-Martínez et al. ANNALS OF ONCOLOGY
- 1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
- (2019) S Domchek et al. ANNALS OF ONCOLOGY
- 171TiPPhase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
- (2019) D Hyman et al. ANNALS OF ONCOLOGY
- 1936PAnalysis of BRCA genes and homologous recombination deficiency (HRD) scores in tumours from patients (pts) with metastatic breast cancer (mBC) in the OlympiAD trial
- (2019) M Robson et al. ANNALS OF ONCOLOGY
- 1979TiPRandomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies
- (2019) C E Heilig et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
- (2019) Mark Robson et al. EUROPEAN JOURNAL OF CANCER
- Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
- (2019) Sara A. Hurvitz et al. ONCOLOGIST
- Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation
- (2018) Leland E. Hull et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort
- (2018) Alexandre Lafourcade et al. BMC CANCER
- BRCA1/2 testing: therapeutic implications for breast cancer management
- (2018) Nadine M. Tung et al. BRITISH JOURNAL OF CANCER
- Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer
- (2018) Carlos H. Barcenas et al. Journal of the National Comprehensive Cancer Network
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study
- (2018) Theresa L. Werner et al. Cancer Medicine
- Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
- (2018) J Ettl et al. ANNALS OF ONCOLOGY
- Breast ultrasonography in the screening protocol for women at hereditary- familial risk of breast cancer: Has the time come to rethink the role of BU according to different risk categories?
- (2018) L. Cortesi et al. INTERNATIONAL JOURNAL OF CANCER
- Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among breast cancer patients.
- (2018) Nadine M. Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-world clinical outcomes and treatment patterns among metastatic breast cancer (MBC) patients with germline BRCA mutation (gBRCAmut).
- (2018) Ruben Quek et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of germline BRCA identification on subsequent breast cancer stage and therapy: Implications for routine screening.
- (2018) Tal Hadar et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.
- (2018) Nadine M. Tung et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).
- (2018) Juan De La Haba et al. JOURNAL OF CLINICAL ONCOLOGY
- PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
- (2018) Jean Abraham et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population based germline testing for primary cancer prevention
- (2018) Ranjit Manchanda et al. Oncotarget
- Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center
- (2018) Melissa K. Frey et al. CANCER
- A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
- (2018) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Disparities in genetic services utilization in a random sample of young breast cancer survivors
- (2018) Christos Nikolaidis et al. GENETICS IN MEDICINE
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Population Based Testing for Primary Prevention: A Systematic Review
- (2018) Ranjit Manchanda et al. Cancers
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
- (2017) Katerina Ancevski Hunter et al. Molecular Diagnosis & Therapy
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study
- (2017) Tarsha Jones et al. Cancer Medicine
- BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
- (2017) Bárbara Alemar et al. PLoS One
- Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals
- (2016) Ashley Stuckey et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Targeted sequencing ofBRCA1andBRCA2across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
- (2016) C. Winter et al. ANNALS OF ONCOLOGY
- Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer
- (2016) Anne Marie McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature
- (2016) Meaghan Krohe et al. Patient Preference and Adherence
- BRCA1andBRCA2Mutation Testing in Young Women With Breast Cancer
- (2016) Shoshana M. Rosenberg et al. JAMA Oncology
- DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
- (2015) Mohammed Aleskandarany et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast Cancer Risks and Risk Prediction Models
- (2015) Christoph Engel et al. Breast Care
- Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast Cancer
- (2015) In Hae Park et al. Clinical Breast Cancer
- Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
- (2015) Christine S. Walsh GYNECOLOGIC ONCOLOGY
- Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
- (2015) Fergus J. Couch et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Factors associated with breast cancer mortality after local recurrence
- (2014) R. Dent et al. Current Oncology
- Preoperative genetic testing affects surgical decision making in breast cancer patients
- (2014) Elizabeth Lokich et al. GYNECOLOGIC ONCOLOGY
- Unique Features of Young Age Breast Cancer and Its Management
- (2014) Han-Byoel Lee et al. Journal of Breast Cancer
- A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women
- (2013) L. Cortesi et al. ANNALS OF ONCOLOGY
- A Statewide Survey of Practitioners to Assess Knowledge and Clinical Practices Regarding Hereditary Breast and Ovarian Cancer
- (2013) Tuya Pal et al. Genetic Testing and Molecular Biomarkers
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
- (2012) N. Mavaddat et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study)
- (2010) Francesco Sardanelli et al. INVESTIGATIVE RADIOLOGY
- First-Line Chemotherapy for Metastatic Breast Cancer
- (2009) Melinda L. Telli et al. Clinical Breast Cancer
- Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
- (2009) William F. Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search